We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

66 hedge funds and large institutions have $1.05B invested in Zentalis Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 36 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 10

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

8% more funds holding

Funds holding: 61 → 66 (+5)

5.34% more ownership

Funds ownership: 74.86% → 80.2% (+5.3%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

18% less capital invested

Capital invested by funds: $1.28B → $1.05B (-$235M)

Holders
66
Holders Change
+5
Holders Change %
+8.2%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
36
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$27.3M
2
RG
Redmile Group
California
+$27M
3
Primecap Management
Primecap Management
California
+$25.3M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$19.2M
5
SAM
Sectoral Asset Management
Quebec, Canada
+$14.4M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$2.86M
2
ZP
Zimmer Partners
New York
-$2.64M
3
Jane Street
Jane Street
New York
-$624K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$593K
5
MIM
MetLife Investment Management
New Jersey
-$178K
Name Holding Trade Value Shares
Change 		Change in
Stake
Axa
26
Axa
France
$5.1M +$1.73M +49,444 +46%
Northern Trust
27
Northern Trust
Illinois
$4.7M +$398K +11,356 +9%
WP
28
Woodline Partners
California
$4.51M +$3.3M +94,158 +215%
AG
29
Artal Group
Luxembourg
$2.86M -$161K -4,600 -5%
Charles Schwab
30
Charles Schwab
California
$2.83M +$731K +20,866 +32%
CCM
31
CAAS Capital Management
New York
$2.2M +$1.48M +42,331 +169%
MWNA
32
Marshall Wace North America
New York
$1.95M – – –
SG Americas Securities
33
SG Americas Securities
New York
$1.68M +$1.6M +45,825 +819%
PCM
34
Pentwater Capital Management
Florida
$1.64M +$1.75M +50,000 New
N
35
Nuveen
North Carolina
$1.33M +$5.92K +169 +0.4%
Tudor Investment Corp
36
Tudor Investment Corp
Connecticut
$1.23M +$1.32M +37,628 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$1.09M +$75.5K +2,157 +7%
Goldman Sachs
38
Goldman Sachs
New York
$1.05M +$643K +18,351 +133%
Bank of America
39
Bank of America
North Carolina
$979K +$455K +12,993 +77%
Allianz Asset Management
40
Allianz Asset Management
Germany
$881K +$944K +26,955 New
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$857K +$117K +3,344 +15%
TD Asset Management
42
TD Asset Management
Ontario, Canada
$735K – – –
Verition Fund Management
43
Verition Fund Management
Connecticut
$634K +$679K +19,400 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$570K +$65K +1,857 +12%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$539K – – –
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$396K -$36.1K -1,031 -8%
MFS
47
Mirabella Financial Services
United Kingdom
$346K +$371K +10,590 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$311K – – –
TRCT
49
Tower Research Capital (TRC)
New York
$302K +$305K +8,724 +1,711%
Wells Fargo
50
Wells Fargo
California
$276K +$112K +3,205 +61%
1
2
3

ZNTL Hedge Fund Activity: Q3 2020 in Review

66 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2020, worth a combined $1.05B — down 18% from $1.28B a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ZNTL positions and 3 closed out — a net gain of 5 holders — while 36 added to existing stakes and 10 trimmed.

The largest buyer was Federated Hermes, opening a new position worth an estimated $27.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.86M.

  • 66 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2020, up from 61 in Q2 2020.
  • Funds reported $1.05B of Zentalis Pharmaceuticals stock for Q3 2020, down 18% quarter-over-quarter.
  • 8 funds opened new Zentalis Pharmaceuticals positions in Q3 2020 and 3 closed out, a net change of +5 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q3 2020 was Federated Hermes, an estimated $27.3M added.
  • The largest Zentalis Pharmaceuticals seller in Q3 2020 was T. Rowe Price Associates, an estimated $2.86M sold.

Based on aggregated 13F filings for Q3 2020.